ERBB2 and breast cancer: Our study found that breast cancer with the HER2+ subtype (HR+/HER2+ and HR−/HER2+) is more prone to abdominal and pelvic metastases than the other BCS, and most of patients with abdominal and pelvic metastases were liver metastases.